{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:01Z","timestamp":1792783441205,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade do Porto","id":[{"id":"https:\/\/ror.org\/043pwc612","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Triple-negative breast cancer (TNBC) is characterized by aggressive biological behavior and poor prognosis. While multimodal treatment is standard, it is frequently withheld from older adults. We evaluated age-related gaps in diagnosis, treatment, and survival, testing whether disparities in clinical management drive worse outcomes in older adults. This 10-year retrospective cohort study (2010\u20132019) included 289 TNBC patients stratified into three age groups (\u2264\u200945, 46\u201369 and \u2265\u200970 years). Clinicopathological features, treatment patterns, adherence to the ESMO-defined standard of care (SOC), and 5-year survival were analyzed. TNBC incidence (10.8%) remained consistent across age groups (\n                    <jats:italic>p\u2009=<\/jats:italic>\n                    \u20090.374). Patients aged\u2009\u2265\u200970 years presented with larger tumors (median: 27\u00a0mm;\n                    <jats:italic>p\u2009=<\/jats:italic>\n                    \u20090.003) and received less intensive diagnostic workups (\n                    <jats:italic>p\u2009&lt;<\/jats:italic>\n                    \u20090.001). SOC adherence was significantly lower in older adults (50.9% vs. 85.9% in those\u2009\u2264\u200945 years;\n                    <jats:italic>p\u2009&lt;<\/jats:italic>\n                    \u20090.001). SOC nonadherence increased the risk for both overall mortality (OM) (HR: 3.47) and breast cancer-specific mortality (BCSM) (sHR: 2.88) (\n                    <jats:italic>p\u2009&lt;<\/jats:italic>\n                    \u20090.001). Failure to achieve pathologic complete response (pCR) tripled mortality risk (OM HR: 3.74,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.016; BCSM sHR: 3.54,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.018). Older women had lower survival rates than did those aged 46\u201369 years for both 5-year overall (56.0% vs. 83.0%;\n                    <jats:italic>p\u2009&lt;<\/jats:italic>\n                    \u20090.001) and breast cancer-specific survival (63.0% vs. 85.0%;\n                    <jats:italic>p\u2009=<\/jats:italic>\n                    \u20090.006). The poorer prognosis in older adults with TNBC is significantly associated with clinical management disparities and low SOC adherence, while histopathological markers of tumor aggressiveness remain highly prevalent across the age spectrum. Daily practice must transition from chronological age-based decisions toward biological fitness to overcome ageism, avoid undertreatment, and ensure personalized therapeutic decision-making.\n                  <\/jats:p>","DOI":"10.1007\/s40520-026-03451-y","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:23:18Z","timestamp":1784888598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-related survival gaps in triple-negative breast cancer: a 10-year real-world analysis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1054-9776","authenticated-orcid":false,"given":"Dinis","family":"Galhardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0579-9988","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Peleteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-836X","authenticated-orcid":false,"given":"Fernando","family":"Os\u00f3rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"3451_CR1","doi-asserted-by":"publisher","first-page":"1586497","DOI":"10.3389\/fpubh.2025.1586497","volume":"13","author":"S Jian","year":"2025","unstructured":"Jian S, Lin W, Tang Y, Yao G (2025) Breast cancer burden (1990\u20132040) in individuals aged 55 and above: a GBD 2021 analysis of global trends, sex-specific risk factors, and intervention impact. Front Public Health 13:1586497. https:\/\/doi.org\/10.3389\/fpubh.2025.1586497","journal-title":"Front Public Health"},{"key":"3451_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12885-025-13862-1","volume":"25","author":"M Elmadani","year":"2025","unstructured":"Elmadani M, Mokaya PO, Omer AAA, Kiptulon EK, Klara S, Orsolya M (2025) Cancer burden in Europe: a systematic analysis of the GLOBOCAN database (2022). BMC Cancer 25:447. https:\/\/doi.org\/10.1186\/s12885-025-13862-1","journal-title":"BMC Cancer"},{"key":"3451_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA (2022) Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer 8:95. https:\/\/doi.org\/10.1038\/s41523-022-00468-0","journal-title":"NPJ Breast Cancer"},{"key":"3451_CR4","doi-asserted-by":"publisher","first-page":"pkaf049","DOI":"10.1093\/jncics\/pkaf049","volume":"9","author":"B Ahmed","year":"2025","unstructured":"Ahmed B, Al-Khames Aga Q, Cheung K-L, De Boniface J, Gnant M, Cardoso M-J et al (2025) Treatment strategies for triple-negative primary breast cancer in older women: a systematic review. JNCI Cancer Spectr 9:pkaf049. https:\/\/doi.org\/10.1093\/jncics\/pkaf049","journal-title":"JNCI Cancer Spectr"},{"key":"3451_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"key":"3451_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-022-00386-1","volume":"8","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H et al (2022) Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer 8:23. https:\/\/doi.org\/10.1038\/s41523-022-00386-1","journal-title":"NPJ Breast Cancer"},{"key":"3451_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.surg.2022.05.026","volume":"172","author":"LM Drapalik","year":"2022","unstructured":"Drapalik LM, Estes A, Sarode AL, Cao L, Shenk RR, Jarrett CM et al (2022) Age disparities in triple-negative breast cancer treatment and outcomes: An NCDB analysis. Surgery 172:821\u2013830. https:\/\/doi.org\/10.1016\/j.surg.2022.05.026","journal-title":"Surgery"},{"key":"3451_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ et al (2024) Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 35:159\u2013182. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016","journal-title":"Ann Oncol"},{"key":"3451_CR9","doi-asserted-by":"publisher","first-page":"102255","DOI":"10.1016\/j.jgo.2025.102255","volume":"16","author":"J Nyqvist-Streng","year":"2025","unstructured":"Nyqvist-Streng J, Somi J, Martikainen J, Olsson M, Helou K, Chamalidou C et al (2025) Age and comorbidity in relation to treatment and survival outcomes in triple-negative breast cancer: A Swedish nationwide registry-based study. J Geriatr Oncol 16:102255. https:\/\/doi.org\/10.1016\/j.jgo.2025.102255","journal-title":"J Geriatr Oncol"},{"key":"3451_CR10","doi-asserted-by":"publisher","unstructured":"Tenhunen O, Penttinen K, Voltz C, Kuitunen H, Turpeinen M Age and frailty in anticancer drug regulatory assessment: a comprehensive cohort study of European marketing authorisations 2012\u20132023. ESMO Real World Data Digit Oncol 2026;11:100663. https:\/\/doi.org\/10.1016\/j.esmorw.2025.100663","DOI":"10.1016\/j.esmorw.2025.100663"},{"key":"3451_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/tbj.13251","volume":"25","author":"MM Kozak","year":"2019","unstructured":"Kozak MM, Xiang M, Pollom EL, Horst KC (2019) Adjuvant treatment and survival in older women with triple negative breast cancer: A Surveillance, Epidemiology, and End Results analysis. Breast J 25:469\u2013473. https:\/\/doi.org\/10.1111\/tbj.13251","journal-title":"Breast J"},{"key":"3451_CR12","doi-asserted-by":"publisher","first-page":"992573","DOI":"10.3389\/fonc.2023.992573","volume":"13","author":"S Pu","year":"2023","unstructured":"Pu S, Xie P, Chen H, Li Y, He J, Zhang H (2023) Evaluation of outcome of chemotherapy for breast cancer patients older than 70 years: A SEER-based study. Front Oncol 13:992573. https:\/\/doi.org\/10.3389\/fonc.2023.992573","journal-title":"Front Oncol"},{"key":"3451_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-025-01380-z","author":"D Otero-Romero","year":"2025","unstructured":"Otero-Romero D, Medina-Mora L, Carrami\u00f1ana-Nu\u00f1o R, Arribas-Del-Amo D (2025) Age as a determining factor in decision-making in older patients with HER2-positive and triple-negative breast cancer. Eur Geriatr Med. https:\/\/doi.org\/10.1007\/s41999-025-01380-z","journal-title":"Eur Geriatr Med"},{"key":"3451_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/abs-23-58","volume":"8","author":"DL Spoer","year":"2024","unstructured":"Spoer DL, Ghyasi N, Thorson TL, Huffman SS, Berger LE, Lava CX et al (2024) Octogenarians with triple negative breast cancer. Ann Breast Surg 8:16. https:\/\/doi.org\/10.21037\/abs-23-58","journal-title":"Ann Breast Surg"},{"key":"3451_CR15","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1200\/JCO.19.02809","volume":"38","author":"C DuMontier","year":"2020","unstructured":"DuMontier C, Loh KP, Bain PA, Silliman RA, Hshieh T, Abel GA et al (2020) Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. J Clin Oncol 38:2558\u20132569. https:\/\/doi.org\/10.1200\/JCO.19.02809","journal-title":"J Clin Oncol"},{"key":"3451_CR16","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S1470-2045(20)30741-5","volume":"22","author":"L Biganzoli","year":"2021","unstructured":"Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH et al (2021) Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet 22:e327\u2013e340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30741-5","journal-title":"Lancet"},{"key":"3451_CR17","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnuson A et al (2021) Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 398:1894\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(21)01789-X","journal-title":"Lancet"},{"key":"3451_CR18","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.jgo.2025.102831","volume":"17","author":"C G\u00f3mez-Moreno","year":"2026","unstructured":"G\u00f3mez-Moreno C, Russo C, Parala-Metz A, Beauplet B, Pillai A, Kumar A et al (2026) Do we need geriatricians in geriatric oncology? A SIOG geriatricians position statement. J Geriatr Oncol 17:102831. https:\/\/doi.org\/10.1016\/j.jgo.2025.102831","journal-title":"J Geriatr Oncol"},{"key":"3451_CR19","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR, Alibhai SMH, Bergerot C, Brintzenhofeszoc K et al (2023) Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. J Clin Oncol 41:4293\u20134312. https:\/\/doi.org\/10.1200\/JCO.23.00933","journal-title":"J Clin Oncol"},{"key":"3451_CR20","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/cancers15051446","volume":"15","author":"F Os\u00f3rio","year":"2023","unstructured":"Os\u00f3rio F, Barros AS, Peleteiro B, Amendoeira I, Fougo JL (2023) Quality Indicators Compliance and Survival Outcomes in Breast Cancer according to Age in a Certified Center. Cancers 15:1446. https:\/\/doi.org\/10.3390\/cancers15051446","journal-title":"Cancers"},{"key":"3451_CR21","doi-asserted-by":"publisher","first-page":"856268","DOI":"10.3389\/fendo.2022.856268","volume":"13","author":"Z Tang","year":"2022","unstructured":"Tang Z, Ji Y, Min Y, Zhang X, Xu W, Zhao L et al (2022) Prognostic Factors and Models for Elderly (\u2265\u200970 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database. Front Endocrinol 13:856268. https:\/\/doi.org\/10.3389\/fendo.2022.856268","journal-title":"Front Endocrinol"},{"key":"3451_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. Ann Intern Med 147:573\u2013577. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010","journal-title":"Ann Intern Med"},{"key":"3451_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-88443-1","volume-title":"AJCC cancer staging manual","author":"American Joint Committee on Cancer","year":"2010","unstructured":"American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, New York, NY","edition":"7"},{"key":"3451_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/bjc.1957.43","volume":"11","author":"HJG Bloom","year":"1957","unstructured":"Bloom HJG, Richardson WW (1957) Histological Grading and Prognosis in Breast Cancer. Br J Cancer 11:359\u2013377. https:\/\/doi.org\/10.1038\/bjc.1957.43","journal-title":"Br J Cancer"},{"key":"3451_CR25","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1148\/radiol.2019182947","volume":"292","author":"RM Mann","year":"2019","unstructured":"Mann RM, Cho N, Moy L, Breast MRI (2019) State of the Art. Radiology 292:520\u2013536. https:\/\/doi.org\/10.1148\/radiol.2019182947","journal-title":"Radiology"},{"key":"3451_CR26","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer. N Engl J Med 384:2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"3451_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","volume":"401","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2023","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2023) Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet 401:1277\u20131292. https:\/\/doi.org\/10.1016\/S0140-6736(23)00285-4","journal-title":"Lancet"},{"key":"3451_CR28","doi-asserted-by":"publisher","first-page":"104524","DOI":"10.1016\/j.breast.2025.104524","volume":"83","author":"F Girardi","year":"2025","unstructured":"Girardi F, Barbieri C, Griguolo G, Iannaccone D, Zurlo C, Dieci MV et al (2025) Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer: A non-inferiority meta-analysis. Breast 83:104524. https:\/\/doi.org\/10.1016\/j.breast.2025.104524","journal-title":"Breast"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-026-03451-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03451-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03451-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:03:07Z","timestamp":1792684987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-026-03451-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3451"],"URL":"https:\/\/doi.org\/10.1007\/s40520-026-03451-y","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. Approval was granted by the BC-ULSSJ Ethics Committee to retrospectively analyze patient data (CE-273-2025).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient written consent was waived because this study was based on a retrospective analysis of pseudoanonymized data from BC-ULSSJ patients.","order":3,"name":"Ethics","label":"Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"217"}}